$OMER
OMEROS CORP Stock $omer

$omer Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000144530513002841 Filed on November 07, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q3
Revenue	$169.0K	$196.0K	$1.417M
YoY Change	-89.32%	-86.17%	43.57%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.890M	$4.210M	$2.740M
YoY Change	4.57%	53.65%	49.73%
% of Gross Profit
Research & Development	$10.19M	$9.420M	$7.764M
YoY Change	8.98%	21.33%	45.91%
% of Gross Profit
Depreciation & Amortization	$80.00K	$70.00K	$60.00K
YoY Change	-11.11%	16.67%	-45.45%
% of Gross Profit
Operating Expenses	$14.07M	$13.63M	$14.45M
YoY Change	54.35%	-5.69%	102.11%
Operating Profit	-$13.90M	-$13.43M	-$13.04M
YoY Change	84.55%	3.05%	111.49%
Interest Expense	-$600.0K	$592.0K	$413.0K
YoY Change	66.67%	43.34%	-21.78%
% of Operating Profit
Other Income/Expense, Net	$150.0K	$154.0K	$159.0K
YoY Change	-6.25%	-3.14%	-7.02%
Pretax Income	-$1.850M	-$13.87M	-$13.28M
YoY Change	-76.07%	4.44%	103.99%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.845M	-$13.87M	-$13.28M
YoY Change	-76.14%	4.47%	103.87%
Net Earnings / Revenue	-1091.72%	-7076.53%	-936.91%
Basic Earnings Per Share
Diluted Earnings Per Share	-$61.08K	-$464.8K	-$514.1K
COMMON SHARES
Basic Shares Outstanding	30.32M shares	29.85M shares	25.86M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.10M	$9.000M	$30.60M
YoY Change	-37.05%	-70.59%	-6.99%
Cash & Equivalents	$1.384M	$1.150M	$1.060M
Short-Term Investments	$12.70M	$7.800M	$29.60M
Other Short-Term Assets	$86.00K	$400.0K	$300.0K
YoY Change	-78.5%	33.33%	50.0%
Inventory	$0.00
Prepaid Expenses	$251.0K
Receivables	$400.0K	$900.0K	$500.0K
Other Receivables	$71.00K	$0.00	$0.00
Total Short-Term Assets	$14.82M	$10.27M	$31.44M
YoY Change	-40.01%	-67.33%	-6.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$939.0K	$952.0K	$685.0K
YoY Change	-9.45%	38.98%	-14.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$113.0K	$76.00K
YoY Change	-37.11%	48.68%	-74.67%
Total Long-Term Assets	$1.718M	$1.744M	$1.324M
YoY Change	-8.37%	31.72%	10.33%
TOTAL ASSETS
Total Short-Term Assets	$14.82M	$10.27M	$31.44M
Total Long-Term Assets	$1.718M	$1.744M	$1.324M
Total Assets	$16.54M	$12.01M	$32.76M
YoY Change	-37.78%	-63.33%	-6.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.329M	$3.361M	$2.702M
YoY Change	-11.51%	24.39%	68.88%
Accrued Expenses	$3.944M	$4.520M	$6.373M
YoY Change	-17.09%	-29.08%	145.12%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.600M	$4.019M	$6.400M
YoY Change		-37.2%	20.75%
Total Short-Term Liabilities	$11.87M	$11.90M	$21.81M
YoY Change	42.04%	-45.44%	38.04%
LONG-TERM LIABILITIES
Long-Term Debt	$14.90M	$16.38M	$8.700M
YoY Change	-25.89%	88.23%	-42.38%
Other Long-Term Liabilities	$8.100M	$7.600M	$3.100M
YoY Change	76.09%	145.16%
Total Long-Term Liabilities	$14.90M	$16.38M	$11.80M
YoY Change	-25.89%	38.78%	-21.85%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.87M	$11.90M	$21.81M
Total Long-Term Liabilities	$14.90M	$16.38M	$11.80M
Total Liabilities	$26.77M	$28.28M	$33.60M
YoY Change	-5.94%	-15.85%	8.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$254.4M	-$252.5M	-$206.8M
YoY Change	18.55%	22.09%
Common Stock	$304.0K	$298.0K	$259.0K
YoY Change	17.37%	15.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$18.38M	-$23.89M	-$820.0K
YoY Change
Total Liabilities & Shareholders Equity	$16.54M	$12.01M	$32.76M
YoY Change	-37.78%	-63.33%	-6.4%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q3
OPERATING ACTIVITIES
Net Income	-$1.845M	-$13.87M	-$13.28M
YoY Change	-76.14%	4.47%	103.87%
Depreciation, Depletion And Amortization	$80.00K	$70.00K	$60.00K
YoY Change	-11.11%	16.67%	-45.45%
Cash From Operating Activities	-$300.0K	-$11.04M	-$7.400M
YoY Change	-97.65%	49.19%	80.05%
INVESTING ACTIVITIES
Capital Expenditures	-$60.00K	-$50.00K	-$90.00K
YoY Change	-85.0%	-44.44%	800.0%
Acquisitions
YoY Change
Other Investing Activities	-$4.870M	$10.50M	-$29.57M
YoY Change	-155.78%	-135.51%	-722.53%
Cash From Investing Activities	-$4.940M	$10.45M	-$29.66M
YoY Change	-159.3%	-135.23%	-725.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$32.30M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.470M	20.00K	30.85M
YoY Change	11.41%	-99.94%	30750.0%
NET CHANGE
Cash From Operating Activities	-300.0K	-11.04M	-7.400M
Cash From Investing Activities	-4.940M	10.45M	-29.66M
Cash From Financing Activities	5.470M	20.00K	30.85M
Net Change In Cash	230.0K	-570.0K	-6.210M
YoY Change	-50.0%	-90.82%	-950.68%
FREE CASH FLOW
Cash From Operating Activities	-$300.0K	-$11.04M	-$7.400M
Capital Expenditures	-$60.00K	-$50.00K	-$90.00K
Free Cash Flow	-$240.0K	-$10.99M	-$7.310M
YoY Change	-98.06%	50.34%	78.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2632000	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3361000	USD
CY2013Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4520000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4757000	USD
CY2013Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	467000	USD
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	252000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	207787000	USD
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	228337000	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	41000	USD
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	511000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4729241	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7518348	shares
CY2012Q4	us-gaap	Assets Assets	26575000	USD
CY2013Q3	us-gaap	Assets Assets	12014000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	24700000	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	10270000	USD
CY2012Q4	us-gaap	Available For Sale Securities Equity Securities Current AvailableForSaleSecuritiesEquitySecuritiesCurrent	20830000	USD
CY2013Q3	us-gaap	Available For Sale Securities Equity Securities Current AvailableForSaleSecuritiesEquitySecuritiesCurrent	7848000	USD
CY2013Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20000000	USD
CY2012Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20000000	USD
CY2013Q3	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	1400000	USD
CY2013Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0925
CY2012Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0925
CY2013Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1100000	USD
CY2012Q4	us-gaap	Cash Cash	1500000	USD
CY2013Q3	us-gaap	Cash Cash	1100000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1150000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1520000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4005000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1060000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-370000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2945000	USD
CY2007Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	12.25
CY2007Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	197478	shares
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25897483	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29849830	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29849830	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25897483	shares
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	298000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	259000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13870000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13276000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30710000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37951000	USD
CY2013Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	128000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	4644000	USD
CY2013Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	7631000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	970000	USD
CY2013Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	222000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	232000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.36
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.46
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.51
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.30
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	458000	USD
CY2013Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	588000	USD
CY2013Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	16000000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y11M
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-3953000	USD
CY2012Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-3953000	USD
CY2013Q3	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2736000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11934000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7270000	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4210000	USD
CY2013Q3	us-gaap	Incentive From Lessor IncentiveFromLessor	4500000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	453000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1702000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-970000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3278000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	3091000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	2987000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	242000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-31000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-408000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-1053000	USD
CY2012Q4	us-gaap	Insurance Recoveries InsuranceRecoveries	3950000	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	592000	USD
	us-gaap	Interest Expense InterestExpense	1360000	USD
	us-gaap	Interest Expense InterestExpense	1768000	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	413000	USD
	us-gaap	Interest Paid InterestPaid	1243000	USD
	us-gaap	Interest Paid InterestPaid	1103000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	32000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	421000	USD
CY2012Q3	us-gaap	Investment Income Net InvestmentIncomeNet	14000	USD
CY2013Q3	us-gaap	Investment Income Net InvestmentIncomeNet	2000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	10000	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12014000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26575000	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11900000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8359000	USD
CY2012Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2013Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	4019000	USD
CY2013Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16376000	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	20103000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Organization</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. Our most clinically advanced product, OMS302 for lens replacement surgery, is derived from our proprietary PharmacoSurgery</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> platform that is designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical and medical procedures. Our efforts are devoted to conducting research and development of our products, developing our patent portfolio, raising capital and commercializing our products.</font></div></div>
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16184000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28061000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9239000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12845000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29399000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21767000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-37951000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-30710000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-13870000	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-13276000	USD
CY2013Q3	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	13630000	USD
	us-gaap	Operating Expenses OperatingExpenses	38045000	USD
	us-gaap	Operating Expenses OperatingExpenses	33791000	USD
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	14453000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-29352000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13434000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-36614000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13036000	USD
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	61700000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	435000	USD
CY2013Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	370000	USD
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	113000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	159000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-30000	USD
CY2012Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	159000	USD
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	154000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	290000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	371000	USD
CY2013Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	39000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	38819000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	22963000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	137000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	235000	USD
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2013Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	391000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	416000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	16120000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	32306000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	29815000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	35945000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	64000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	351000	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	952000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1037000	USD
CY2012Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1934000	USD
CY2013Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	881000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	4596000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9420000	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7764000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22568000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26111000	USD
CY2013Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	679000	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	679000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-214577000	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-252528000	USD
	us-gaap	Revenues Revenues	4439000	USD
CY2012Q3	us-gaap	Revenues Revenues	1417000	USD
CY2013Q3	us-gaap	Revenues Revenues	196000	USD
	us-gaap	Revenues Revenues	1431000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2276000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4364000	USD
CY2012Q3	us-gaap	Share Based Compensation ShareBasedCompensation	576000	USD
CY2013Q3	us-gaap	Share Based Compensation ShareBasedCompensation	2211000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.84
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.89
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.87
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.88
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0166
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0083
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0105
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0165
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3873323	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.26
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	166208	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	7.42
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1734301	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.73
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.32
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.63
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.77
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	25351000	USD
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6909332	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5390582	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.18
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.19
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	24973000	USD
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6605953	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	6.08
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.29
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.31
CY2013Q2	us-gaap	Share Price SharePrice	4.14
CY2012Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M
CY2013Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M
CY2013Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	21525000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M25D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M2D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y3M
CY2013Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3903004	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	49343	shares
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	-23893000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-6531000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from those estimates.</font></div></div>
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29844507	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27984133	shares
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25834730	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23578724	shares
CY2012Q4	omer	Accrued Adminstrative Review AccruedAdminstrativeReview	0	USD
CY2013Q3	omer	Accrued Adminstrative Review AccruedAdminstrativeReview	1064000	USD
CY2013Q3	omer	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	697000	USD
CY2012Q4	omer	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	1842000	USD
CY2013Q3	omer	Accrued Contract Research Costs AccruedContractResearchCosts	594000	USD
CY2012Q4	omer	Accrued Contract Research Costs AccruedContractResearchCosts	1447000	USD
CY2013Q3	omer	Accrued Legal Fees AccruedLegalFees	740000	USD
CY2012Q4	omer	Accrued Legal Fees AccruedLegalFees	323000	USD
	omer	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-511000	USD
	omer	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-41000	USD
CY2012Q1	omer	Classof Warrantor Right Extension Period ClassofWarrantorRightExtensionPeriod	P1Y
CY2010Q4	omer	Classof Warrantor Right Numberof Warrants Issued ClassofWarrantorRightNumberofWarrantsIssued	3	warrant
CY2007Q1	omer	Classof Warrantor Right Periodfor Issuance ClassofWarrantorRightPeriodforIssuance	P5Y
CY2013Q3	omer	Deferred Rent Less Lease Incentives DeferredRentLessLeaseIncentives	3100000	USD
CY2012	omer	Deferred Rent Reclassification DeferredRentReclassification	959000	USD
	omer	Increase Decreasein Accrued Settlement Costs IncreaseDecreaseinAccruedSettlementCosts	3953000	USD
	omer	Increase Decreasein Accrued Settlement Costs IncreaseDecreaseinAccruedSettlementCosts	0	USD
	omer	Lease Extension Period LeaseExtensionPeriod	P5Y
CY2012Q4	omer	Litigation Settlement Amount LitigationSettlementAmount	3950000	USD
	omer	Operating Lease Number Of Additional Renewal Option OperatingLeaseNumberOfAdditionalRenewalOption	2	Leases
	omer	Reduction Of Equipment Cost Basis Due To Assets Purchased With Grant Funding ReductionOfEquipmentCostBasisDueToAssetsPurchasedWithGrantFunding	0	USD
	omer	Reduction Of Equipment Cost Basis Due To Assets Purchased With Grant Funding ReductionOfEquipmentCostBasisDueToAssetsPurchasedWithGrantFunding	59000	USD
	omer	Sales Agreement Aggregate Offering Price Common Stock SalesAgreementAggregateOfferingPriceCommonStock	44400000	USD
	omer	Sales Agreement Commission Percentage SalesAgreementCommissionPercentage	0.02
	omer	Sales Agreement Termination Period SalesAgreementTerminationPeriod	P10D
CY2013Q3	omer	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber	3036009	shares
CY2012Q1	omer	Warrant Expiration Date WarrantExpirationDate	2013-03-29
CY2013Q1	omer	Warrant Expiration Date WarrantExpirationDate	2014-03-29
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001285819
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30319951	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	OMEROS CORP
	dei	Trading Symbol TradingSymbol	OMER

Files In Submission

Name	View Source	Status
0001445305-13-002841-index-headers.html	Edgar Link	pending
0001445305-13-002841-index.html	Edgar Link	pending
0001445305-13-002841.txt	Edgar Link	pending
0001445305-13-002841-xbrl.zip	Edgar Link	pending
exhibit101seventhamendment.htm	Edgar Link	pending
exhibit102formofoptiongran.htm	Edgar Link	pending
exhibit1212013930.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
omer-20130930.xml	Edgar Link	completed
omer-20130930.xsd	Edgar Link	pending
omer-20130930_cal.xml	Edgar Link	unprocessable
omer-20130930_def.xml	Edgar Link	unprocessable
omer-20130930_lab.xml	Edgar Link	unprocessable
omer-20130930_pre.xml	Edgar Link	unprocessable
omer-2013930x10q.htm	Edgar Link	pending
omer-ex311_2013930xq3.htm	Edgar Link	pending
omer-ex312_2013930xq3.htm	Edgar Link	pending
omer-ex321_2013930xq3.htm	Edgar Link	pending
omer-ex322_2013930xq3.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OMER
OMEROS CORP Stock $omer

2013 Q4 Form 10-Q Financial Statement

#000144530513002841 Filed on November 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OMER OMEROS CORP Stock $omer

2013 Q4 Form 10-Q Financial Statement

#000144530513002841 Filed on November 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OMER
OMEROS CORP Stock $omer